365 related articles for article (PubMed ID: 22880466)
1. [Ovarian cancer--modern approach to its origin and histogenesis].
Nowak-Markwitz E; Spaczyński M
Ginekol Pol; 2012 Jun; 83(6):454-7. PubMed ID: 22880466
[TBL] [Abstract][Full Text] [Related]
2. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
3. Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin.
Morency E; Leitao MM; Soslow RA
Int J Gynecol Pathol; 2016 May; 35(3):222-9. PubMed ID: 26630225
[TBL] [Abstract][Full Text] [Related]
4. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.
Marquez RT; Baggerly KA; Patterson AP; Liu J; Broaddus R; Frumovitz M; Atkinson EN; Smith DI; Hartmann L; Fishman D; Berchuck A; Whitaker R; Gershenson DM; Mills GB; Bast RC; Lu KH
Clin Cancer Res; 2005 Sep; 11(17):6116-26. PubMed ID: 16144910
[TBL] [Abstract][Full Text] [Related]
5. Histological classification of ovarian cancer.
Kaku T; Ogawa S; Kawano Y; Ohishi Y; Kobayashi H; Hirakawa T; Nakano H
Med Electron Microsc; 2003 Mar; 36(1):9-17. PubMed ID: 12658347
[TBL] [Abstract][Full Text] [Related]
6. Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?
Moss EL; Evans T; Pearmain P; Askew S; Singh K; Chan KK; Ganesan R; Hirschowitz L
Int J Gynecol Cancer; 2015 Sep; 25(7):1201-7. PubMed ID: 26035124
[TBL] [Abstract][Full Text] [Related]
7. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
[TBL] [Abstract][Full Text] [Related]
8. The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications.
Meinhold-Heerlein I; Fotopoulou C; Harter P; Kurzeder C; Mustea A; Wimberger P; Hauptmann S; Sehouli J
Arch Gynecol Obstet; 2016 Apr; 293(4):695-700. PubMed ID: 26894303
[TBL] [Abstract][Full Text] [Related]
9. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
[TBL] [Abstract][Full Text] [Related]
11. Ovarian cancer update: lessons from morphology, molecules, and mice.
Cho KR
Arch Pathol Lab Med; 2009 Nov; 133(11):1775-81. PubMed ID: 19886711
[TBL] [Abstract][Full Text] [Related]
12. [Ovarian carcinoma. Do the subtypes reflect different diseases?].
Köbel M
Pathologe; 2008 Nov; 29 Suppl 2():160-2. PubMed ID: 18709371
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
[TBL] [Abstract][Full Text] [Related]
14. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.
Wu R; Hendrix-Lucas N; Kuick R; Zhai Y; Schwartz DR; Akyol A; Hanash S; Misek DE; Katabuchi H; Williams BO; Fearon ER; Cho KR
Cancer Cell; 2007 Apr; 11(4):321-33. PubMed ID: 17418409
[TBL] [Abstract][Full Text] [Related]
15. New insights in the pathophysiology of ovarian cancer and implications for screening and prevention.
Nezhat FR; Apostol R; Nezhat C; Pejovic T
Am J Obstet Gynecol; 2015 Sep; 213(3):262-7. PubMed ID: 25818671
[TBL] [Abstract][Full Text] [Related]
16. [Recent advances on ovarian epithelial cancer: definition, subtypes and pathologic features].
Guo DH; Zheng WX
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):624-8. PubMed ID: 24314254
[No Abstract] [Full Text] [Related]
17. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
Obata K; Morland SJ; Watson RH; Hitchcock A; Chenevix-Trench G; Thomas EJ; Campbell IG
Cancer Res; 1998 May; 58(10):2095-7. PubMed ID: 9605750
[TBL] [Abstract][Full Text] [Related]
18. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.
Kurman RJ; Shih IeM
Am J Surg Pathol; 2010 Mar; 34(3):433-43. PubMed ID: 20154587
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples.
Grisaru-Granovsky S; Salah Z; Maoz M; Pruss D; Beller U; Bar-Shavit R
Int J Cancer; 2005 Jan; 113(3):372-8. PubMed ID: 15455382
[TBL] [Abstract][Full Text] [Related]
20. Proteomic analyses of serous and endometrioid epithelial ovarian cancers - cases studies - molecular insights of a possible histological etiology of serous ovarian cancer.
Longuespée R; Gagnon H; Boyon C; Strupat K; Dauly C; Kerdraon O; Ighodaro A; Desmons A; Dupuis J; Wisztorski M; Vinatier D; Fournier I; Day R; Salzet M
Proteomics Clin Appl; 2013 Jun; 7(5-6):337-54. PubMed ID: 23589350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
